Abbott (NYSE:ABT) this week released a wealth of new data on its neuromod technology, which it acquired in its $25 billion buy of St. Jude Medical (NYSE:STJ).
Presentations included an analysis from the Sunburst study of St. Jude’s BurstDR technology, a sub-study of optimal BurstDR programming, an analysis of non-rechargeable spinal cord stimulation devices and a series of data presentations showing the efficacy of BurstDR stimulation for treating chronic pain.
The BurstDR tech, which is designed to improve spinal cord stimulation effectiveness for chronic pain patients, originated with research by Dr. Dirk De Ridder of Dunedin, New Zealand’s University of Otago, who filed the initial patents back in 2004. The technology uses intermittent “burst” pulses which attempt to mimic the body’s natural nerve impulse patterns.
Data from the studies was presented at the 2017 North American Neuromodulation Society’s annual meeting.